Showing 2071-2080 of 2192 results for "".
- Phase 3 Pivotal Study of Trofinetide for Rett Syndrome Initiatedhttps://practicalneurology.com/news/phase-3-pivotal-study-of-trofinetide-for-rett-syndrome-initiated/2469065/The phase 3 LAVENDER placebo-controlled study to evaluate efficacy and safety of trofinetide for treatment of Rett syndrome has been initiated. Presenting primarily in girls and young women at age 6 to 18 months, individuals with Rett syndrome that causes cognitive, sensory, motor, and autonomic
- New Category 3 CPT Code for Eye-Tracking Test for Concussion Diagnosishttps://practicalneurology.com/news/new-category-3-cpt-code-for-eye-tracking-test-for-concussion-diagnosis/2469064/The American Medical Association (AMA) has confirmed the addition of a new code for an eye-tracking diagnostic procedure for concussion (Eyebox; Oculogica, New York, New York).The category 3 CPT Code, 0X17T, eye movement analysis test without spatial calibration,allows clinicians to appropriately
- ALS Phase 3 Clinical Trial of Neurotrophic Growth Factor-Producing Stem Cells Progress With Data Safety Monitoring Boardhttps://practicalneurology.com/news/als-phase-3-clinical-trial-progress-with-data-safety-monitoring-board/2469061/A 2nd, pre-specified interim analysis for a trial (NCT03280056) of neurotrophic factor (NTF)-secreting stem-cell therapy (NurOwn; BrainStorm Cell Therapeutics, New York, NY) for treatment of amyotrophic lateral sclerosis (ALS) has been announced. This review was done by an independent Data Safety
- FDA Approves Onabotulinumtoxin A for Treatment of Lower Limb Spasticity in Children Without Cerebral Palsyhttps://practicalneurology.com/news/fda-approves-onabotulinumtoxin-a-for-treatment-of-lower-limb-spasticity-in-children-without-cerebral-palsy/2469058/The Food and Drug Administration (FDA) has approved onabotulinumtoxinA (Botox; Allergan, Madison, NJ) for the treatment of lower limb spasticity in children age 2 to 17 years. This approval is based on a phase 3 study (NCT03017729) eva
- High Levels of Trans Fatty Acids Increase Risk of Dementiahttps://practicalneurology.com/news/high-levels-of-trans-fatty-acids-increase-risk-of-dementia/2469056/People who have more trans fats in their blood may be more likely to develop dementia years later, according to a study published in the October 23, 2019, online issue of Neurology. After adjusting for other factors that could affect the risk of dementia, such as high blood pressu
- Evidence for Using Sex-Specific Cut-Off Scores to Diagnose Mild Cognitive Impairmenthttps://practicalneurology.com/news/mild-cognitive-impairment-prevalence-is-higher-in-women-than-men-when-sex-specific-score-cut-offs-are-used/2469045/Mild cognitive impairment (MCI), which progresses to Alzheimer’s disease (AD) within 5 years for approximately half of those diagnosed, is identified when an individual’s score is below established cut-off scores on cognitive tests. It has been suggested that because women, on average
- New Sumatriptan Intranasal Spray Launch Announcedhttps://practicalneurology.com/news/new-sumatriptan-intranasal-spray-launch-announced/2469038/An intranasal form of sumatriptan (Tosymra Nasal Spray; Upsher-Smith Laboratories, Maple Grove, MN), approved by the Food and Drug Administration (FDA) earlier this year, has been launched for acute treatment of migraine attack with or without aura in adults. This is a new strengt
- FDA Approves Expanded Indication for AbobotulinumtoxinA—Upper Limb Spasticity in Children Age 2 or Morehttps://practicalneurology.com/news/fda-approves-expanded-indication-for-abobotulinumtoxinaupper-limb-spasticity-in-children-age-2-or-more/2469033/The Food and Drug Administration (FDA) has approved expanded indications for abobotulinumtoxinA (Dysport; Ipsen Group, Cambridge, MA) to include treatment of upper limb spasticity in children age 2 years or more, excluding spasticity caused by cerebral palsy (CP). With this approval, abobotulinum
- Soticlestat Reduces Seizure Frequency in Developmental and Epileptic Encephalopathies in Phase 2 Trialhttps://practicalneurology.com/news/soticlestat-reduces-seizure-frequency-in-developmental-and-epileptic-encephalopathies-in-phase-2-trial/2469032/Initial findings of the ENDYMION trial (NCT03635073) suggest soticlestat (OV935/TAK935; Ovid Therapeutics, New York, NY) reduces the frequency of seizures in people with rare developmental and epileptic encephalopathies (DEE), includin
- Fenfluramine, Antiseizure Medication With Durable Profound Seizure Reduction to Be Resubmitted to FDA This Monthhttps://practicalneurology.com/news/fenfluramine-antiseizure-medication-with-durable-profound-seizure-reduction-to-be-resubmitted-to-fda-this-month/2469023/In clinical trials, treatment with low dose fenfluramine (Fintepla; Zogenix, Emeryville, CA) has resulted in large consistent durable reductions in seizure frequency for individuals with Dravet’s syndrome (DS). In 2 pivotal clinical trials, children age 2 to 18 years, who were treated with